Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.

ABSTRACT:

Background

Understanding individual differences in susceptibility to antidepressant therapy side-effects is essential to optimize the treatment of depression.

Method

We performed genome-wide association studies (GWAS) to search for genetic variation affecting the susceptibility to side-effects. The analysis sample consisted of 1439 depression patients, successfully genotyped for 421K single nucleotide polymorphisms (SNPs), from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Outcomes included four indicators of side-effects: general side-effect burden, sexual side-effects, dizziness and vision/hearing-related side-effects. Our criterion for genome-wide significance was a prespecified threshold ensuring that, on average, only 10% of the significant

SUBMITTER: Clark SL 

PROVIDER: S-EPMC3627503 | biostudies-literature | 2012 Jun

REPOSITORIES: biostudies-literature